, Tracking Stock Market Picks
Enter Symbol:
Achillion Pharmaceuticals, Inc. (ACHN) [hlAlert]

down 26.29 %

Achillion Pharmaceuticals, Inc. (ACHN) upgraded to Outperform with price target $5 by Wedbush Morgan

Posted on: Tuesday,  Feb 2, 2010  9:25 AM ET by Wedbush Morgan

Wedbush Morgan rated Outperform Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on 02/02/2010. Previously Wedbush Morgan rated Underperform Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on
10/21/2009., when the stock price was $1.85. Since then, Achillion Pharmaceuticals, Inc. has gained 35.68% as of 02/02/2010's recent price of $2.51.
If you would have followed the previous Wedbush Morgan's recommendation on ACHN, you would have lost 26.29% of your investment in 104 days.

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.

Since 1980, WEDBUSH has used its private equity discipline to invest in under-valued and capital constrained public and private companies that have a significant potential for appreciation. The firm invests with high quality management teams with domain expertise and expects management to retain or make a personally significant equity investment.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/2/2010 9:25 AM Buy
2.51 5.00
as of 12/31/2010
1 Week up  18.40 %
1 Month up  50.69 %
3 Months up  42.71 %
1 YTD up  91.00 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/21/2009 9:25 AM Sell
1.85 2.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy